Annovis Bio Inc. ANVS Archives - Page 2 of 4

WednesdayNov 13, 2024 8:45 am

Annovis Bio Inc. (NYSE: ANVS) Concludes Q3 with Strategic Milestones and FDA-Cleared Phase 3 Program for Alzheimer’s Disease

Annovis provided business and financial updates for Q3 2024, spotlighting progress toward pivotal buntanetap trials in Alzheimer’s disease. The FDA has cleared Annovis to proceed with a Phase 3 program, which will include a 6-month study to confirm buntanetap’s symptomatic benefits (beginning Q1 2025) and an 18-month study to explore potential disease-modifying effects. Matthew Peterson, Ph.D., was appointed as Senior Clinical Scientist and will oversee quality and rigor in upcoming clinical trials. Annovis filed three new patents for innovative combination therapies, involving buntanetap with Trulicity (dulaglutide), Viagra (sildenafil), and a combination of all three. As of Nov. 8, 2024, the…

TuesdayNov 12, 2024 8:20 am

QualityStocksNewsBreaks – Annovis Bio Inc. CEO to Showcase Buntanetap’s Dual Benefits for Alzheimer’s and Parkinson’s at NIA Workshop

Annovis Bio (NYSE: ANVS) announced that its President and CEO, Dr. Maria Maccecchini, will speak at the National Institute on Aging’s (NIA) workshop, “Dementia with Lewy Bodies: Filling the Gaps in Translational and Clinical Research.” Scheduled for Nov. 13, 2024, Dr. Maccecchini’s presentation, titled “One Drug, Dual Effect: Buntanetap Improves Cognitive and Motor Functions, Benefiting Alzheimer's and Parkinson's Patients. A Potential Path for Lewy Body Dementia?” will explore the potential of Annovis’s lead drug candidate, Buntanetap, to address neurodegenerative diseases by enhancing cognitive and motor functions, with implications for Lewy body dementia treatment. To view the full press release, visit…

TuesdayNov 05, 2024 8:00 am

Annovis Bio Inc. (NYSE: ANVS) Highlights Buntanetap Results at 17th Clinical Trials on Alzheimer’s Disease (‘CTAD’) 2024 Conference

Two posters were presented by Annovis’ President and CEO, Dr. Maria Maccecchini, focusing on the company’s lead drug candidate buntanetap and its performance in clinical trials for the treatment of Alzheimer’s disease (“AD”). A leading event for the Alzheimer’s research community, CTAD 2024, brought together key members of pharmaceutical companies, academic research centers, and patient advocacy groups to discuss avenues for AD treatment. Buntanetap has been shown to significantly improve cognition in early AD patients, both ApoE4 carriers and non-carriers, and normalize biomarkers associated with AD pathology. The company is preparing for Phase 3 clinical trials for buntanetap in early-stage…

ThursdayOct 31, 2024 9:10 am

QualityStocksNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) CEO Details Promising Phase 3 Path for Alzheimer’s Treatment on The BioMedWire Podcast

Annovis Bio (NYSE: ANVS) led by Founder, President and CEO Dr. Maria Maccecchini, shares exciting developments regarding its pioneering Alzheimer’s and Parkinson’s drug candidate, buntanetap. In her interview on IBN’s BioMedWire Podcast, Dr. Maccecchini discusses Annovis Bio’s recent FDA clearance to proceed with pivotal Phase 3 trials for early-stage Alzheimer’s patients, a critical step toward potential market approval. Highlighting buntanetap’s unique mechanism that targets multiple neurotoxic proteins, Dr. Maccecchini explains the potential for superior outcomes compared to existing therapies, emphasizing the drug’s demonstrated short-term efficacy and differentiated approach in neurodegenerative treatment. To view the full press release, visit https://ibn.fm/bjoc8 About…

TuesdayOct 29, 2024 12:29 pm

QualityStocksNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Moving Closer to Providing Much-Needed Treatments to Patients

Annovis Bio (NYSE: ANVS) is a late-stage clinical drug platform company pioneering novel therapies for neurodegenerative diseases. Recent clinical trials of the company’s lead compound yielded encouraging results, with buntanetap shown to improve cognition in both Alzheimer’s and Parkinson’s patients. The company also introduced a new crystalline form of buntanetap with improved properties, “offering significant advantages over the less structured, old semi-crystalline form,” according to a recent article. “Annovis filed the new crystalline form with the International Patent Cooperation Treaty and a provisional patent for the manufacturing of this crystalline form, covering the entire synthesis process. The company also received…

FridayOct 25, 2024 9:45 am

Annovis Bio Inc. (NYSE: ANVS) Gets FDA Clearance for Buntanetap Pivotal Phase 3 Trials, Market Enthusiasm Highlighted in GuruFocus Article

Financial research platform GuruFocus underlines Annovis’ unique approach to tackling neurodegenerative conditions such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”). The FDA's decision to allow the company to go to Phase 3, points to the fact that lead drug candidate buntanetap may be an effective treatment for AD, one of the most critical diseases in an aging society. Buntanetap has been shown to significantly improve cognition in early AD patients, both by itself or on top of existing therapies. The Phase 3 program will consist of two trials: a 6-month study aimed at confirming buntanetap’s symptomatic benefits and an…

WednesdayOct 23, 2024 9:45 am

Annovis Bio Inc. (NYSE: ANVS) Receives FDA Clearance to Initiate Pivotal Phase 3 Alzheimer’s Studies, Paving the Way for NDA Filings

Annovis Bio received FDA clearance to move forward with Phase 3 trials for buntanetap following an End-of-Phase 2 meeting on October 10, 2024. The pivotal trials will investigate buntanetap’s short-term symptomatic effects and potential long-term disease-modifying benefits in early-stage Alzheimer’s disease (“AD”) patients. Annovis Bio is targeting potential NDA submission within one year of the study’s initiation for symptomatic treatment, based on the results of a well-executed 6-month trial. The FDA raised no safety concerns regarding buntanetap and supported the use of its new crystal form in development. Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company focused on…

FridayOct 04, 2024 11:15 am

Annovis Bio Inc. (NYSE: ANVS) Seeking to Strengthen Intellectual Property Portfolio, Protecting Multifaceted Approach for Treatment of Neurodegenerative Diseases

Annovis Bio recently filed three new patents covering combinations of buntanetap, its lead compound, with a GLP-1 agonist (such as dulaglutide/Trulicity) and with PDE5 inhibitors (such as sildenafil/Viagra), as well as a combination of all three The company believes these combinations create a broader approach to treating neurodegenerative diseases Preclinical studies have demonstrated these combinations significantly improve cognition in Alzheimer’s mouse models Combinations of buntanetap with PDE5 inhibitors and GLP-1 agonists are now ready to enter phase 3 clinical studies (buntanetap is in phase 3, and a number of PDE5 inhibitors and GLP-1 agonists are already on the market) Annovis…

WednesdaySep 25, 2024 9:00 am

Annovis Bio Inc. (NYSE: ANVS) Presented Recent Achievements and Strategic Direction at H.C. Wainwright Investment Conference

The event was attended by Annovis Founder, President and CEO Maria L. Maccecchini, Ph.D. Dr. Maccecchini discussed the company’s notable achievements and plans for the future and held a Q&A session with attendees. The company CEO also participated in an expert panel discussing innovative non-amyloid approaches in Alzheimer’s disease. Recent clinical trials of the company’s lead compound buntanetap obtained encouraging results and was shown to improve cognition in both Alzheimer’s and Parkinson’s patients. Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), participated in…

FridaySep 20, 2024 2:30 pm

QualityStocksNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Stands Distinct from Industry Players with Buntanetap

Annovis Bio (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, secured U.S. patent No. 12,042,482 covering methods for treating traumatic brain injury (“TBI”) and nerve injury with buntanetap, the company’s lead drug candidate. “Buntanetap (formerly Posiphen) targets neurodegeneration by inhibiting the formation of multiple neurotoxic proteins such as amyloid beta, tau, alpha-synuclein, and TDP43; by inhibiting their translation, the drug improves synaptic transmission, axonal transport, reduces neuroinflammation, and prevents nerve cells from dying. Unlike monoclonal antibody therapies, buntanetap is an orally available small molecule that inhibits multiple neurotoxic proteins simultaneously, making it a promising solution…

Site Search

Company Search

Tag: Annovis Bio Inc. ANVS